Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-2570 in moderate-to-severe plaque psoriasis
NCT06278350Phase 2Completed
- Sponsor
- InventisBio
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of D-2570 in plaque psoriasis (4 arms), sponsored by InventisBio. Primary endpoint: Percentage of subjects with at least 75% improvement in Psoriasis Area and Severity Index at 12 weeks. Started Jan 2024; status: completed.
02
Drugs
D-2570
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06278350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278350.